论文部分内容阅读
目的研究波立维用于预防短暂性脑缺血发作(TIA)终点事件发生的效果。方法将ESSEN评分≥3分的TIA患者服用波立维(波立维组)及服用阿司匹林(阿司匹林组),以再次TIA发作或急性脑梗死的发生作为终点事件进行评价。结果波立维组14例再次发生脑血管事件,阿司匹林组26例再次发生脑血管事件。两组1 a内TIA及脑梗死卒中事件的比较有统计学意义(P<0.01)。结论对于ESSEN评分≥3分的TIA患者经波立维治疗后效果优于阿司匹林。
Objective To study the effect of bevacizumab in preventing the occurrence of transient ischemic attack (TIA). Methods TIA patients with an ESSEN score of ≥3 were enrolled in the BOLV (aspirin group) and aspirin group (aspirin group). TIA onset or acute cerebral infarction was assessed as the end point. Results Cerebrovascular events occurred again in 14 cases in the Bolivian group and cerebrovascular events occurred in 26 cases in the Aspirin group. The incidence of stroke and TIA in both groups within 1 year was statistically significant (P <0.01). Conclusion TIA patients with ESSEN score ≥3 were better than aspirin after wave therapy.